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Abstract
The relationship between baseline fasting C-peptide (FCP) and glucose control
was examined in insulin-naïve people with type 2 diabetes inadequately con-
trolled with oral antihyperglycaemic drugs commencing basal insulin glargine
300 U/mL (Gla-300) or 100 U/mL (Gla-100) in the absence of sulfonylurea/
glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867)
were stratified according to baseline FCP (≤0.40, >0.40-1.20, >1.20 nmol/L);
11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body
weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic
control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insu-
lins. However, end-of-study insulin dose was greater with higher FCP for both
insulins. More people with lower baseline FCP experienced hypoglycaemia with
both insulins, but with numerically lower incidence for Gla-300 versus Gla-100
across all FCP groups for all definitions (time periods and levels) of
hypoglycaemia. This suggests that Gla-300 might be particularly advantageous for
people who are at higher risk of hypoglycaemia.
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1 | INTRODUCTION
People with type 2 diabetes (T2D) represent a heterogenous popu-
lation and recent cluster analyses have proposed five different dia-
betes phenotypes using age, body mass index (BMI), glycaemia,
homoeostasis model estimates and islet autoantibodies.1,2 Based
on phenotype, people have a different risk for hypoglycaemia dur-
ing insulin therapy and a different risk for developing diabetic
complications.1,3 Among the predictive factors of the
hypoglycaemia risk when starting basal insulin, lower BMI and sul-
fonylurea use are well established.4,5 Fasting C-peptide(FCP), a sur-
rogate biomarker of ß-cell function, has been reported as an
additional predictive biomarker for hypoglycaemia risk in insulin-
naïve people with T2D commencing insulin glargine 100 U/mL
(Gla-100) as add-on therapy to oral antihyperglycaemic drugs
(OADs) including sulfonylurea.6
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Insulin glargine 300 U/mL (Gla-300), a 3-fold more concen-
trated formulation of Gla-100 with improved pharmacokinetic and
pharmacodynamic properties compared with Gla-100 at bioequiva-
lent doses,7 reduced the risk of hypoglycaemia at similar levels of
glycaemic control compared with Gla-100 in different T2D study
populations enrolled in the EDITION clinical trial programme.8 The
aim of the present post hoc analysis was to explore the risk of
hypoglycaemia on basal insulin treatment with Gla-300 or Gla-100
in the insulin-naïve T2D population not receiving sulfonylurea/
glinides in the EDITION 3 trial,9 analysed according to baseline FCP
levels.
2 | MATERIALS AND METHODS
2.1 | Study and participant selection
Participant-level data from the 26-week EDITION 3 trial of insulin-naïve
people with T2D inadequately controlled (HbA1c > 53 mmol/mol;
>7.0%) on OADs (metformin or/and dipeptidyl peptidase-4 inhibitors but
not using sulfonylurea/glinides) were analysed. The study used a forced
titration algorithm with once-weekly dose adjustments by 2-8 U/day
based on patient's self-measured blood glucose, targeting a fasting
plasma glucose (FPG) of 4.4 to 5.6 mmol/L (80-100 mg/dL).9
2.2 | Outcomes
Clinical characteristics were determined at baseline and after the
introduction and titration of the basal insulins (Gla-300 and Gla-100,
Sanofi, Paris, France). These were administered once-daily at the same
time between dinner and bedtime. All clinical outcomes were assessed
over the 26-week study period according to three predefined baseline
FCP groups (≤0.40, >0.40-1.20, >1.20 nmol/L). As FCP cut-offs often
vary across studies we used the same FCP cut-offs for subgroups as
those used in our previous study analysing insulin-naïve people with
T2D commencing Gla-100,6 but with the two highest groups merged,
as the >2.00 nmol/L group was small and similar to the group below
it. The aim was to approximate subpopulations ranging from dominant
insulin deficiency to dominant insulin resistance. Hypoglycaemia was
defined as a confirmed plasma glucose (PG) of ≤3.9 or <3.0 mmol/L
(≤70 or <54 mg/dL), or severe hypoglycaemia requiring third-party
assistance. Nocturnal hypoglycaemia was defined as an event occur-
ring from midnight to 05:59 AM.
2.3 | Statistical analysis
Analyses used descriptive statistics, and results are shown as mean
(SD) unless stated otherwise. Hypoglycaemia incidences and event rates
were compared as described in the primary study paper.9 Plots displaying
the relationship between hypoglycaemia frequency and baseline FCP
levels were derived from negative binomial regression analysis.
3 | RESULTS
3.1 | Participant characteristics and demographic
variables
From a total of 878 people who participated in the EDITION 3 trial,
867 had baseline FCP measured and were included in the analysis. Base-
line demographic and clinical characteristics according to baseline FCP
groups are given in Table S1. The majority (70.9%) had FCP levels of
>0.40 to 1.20 nmol/L, 11.0% had levels of ≤0.40 nmol/L, and 18.1% had
FCP > 1.20 nmol/L. Mean age and glycaemic variables were similar
across all three FCP and insulin groups, whereas body weight and BMI
were lowest in the ≤0.40 nmol/L FCP groups and highest in the FCP
> 1.20 nmol/L groups. Participants in the highest FCP groups had lower
estimated glomerular filtration rates (eGFR) than those in the lowest FCP
groups; the distribution of race groups also differed.
3.2 | Glycaemic control
The mean reductions in HbA1c observed at week 26 ranged from
1.35% to 1.67% (14.8 to 17.7 mmol/mol) across FCP groups with
numerically greater reductions with Gla-100 versus Gla-300 in the
two lowest FCP groups (Table 1). The percentage of people achieving
the target HbA1c level of <7.0% (<53 mmol/mol) at week 26 was
comparable across all FCP groups (42%-48%), except for Gla-100 in
the ≤0.40 nmol/L FCP group (35%) (Figure S1).
From similar baseline FPG levels in each FCP group, the mean
FPG changes after 26 weeks ranged from −3.0 to −4.2 mmol/L
(Table 1). There was a trend of smaller FPG reductions with higher
baseline FCP, particularly observed in Gla-300 groups (from −3.7 to
−3.0 mmol/L), resulting in the highest FPG levels at 26 weeks for Gla-
300 and Gla-100 (7.1/6.8 mmol/L) in the >1.20 nmol/L FCP groups.
The percentage of participants achieving target FPG of ≤5.6 mmol/L
(≤100 mg/dL) at 26 weeks was highest in the ≤0.40 nmol/L FCP
groups and steadily decreased in the higher FCP groups (Gla-300:
from 29% to 27% and 19%; Gla-100: from 33% to 31% and 24%)
(Figure S1).
3.3 | Insulin doses
The mean Gla-300 and Gla-100 starting doses ranged from 0.19 to
0.20 U/kg/day across the three FCP groups, but daily doses were thus
higher in the highest FCP groups given the body weight differences.
Both insulins were steadily titrated during 26 weeks in each FCP group
reaching highest mean doses per kilogram in the >1.20 nmol FCP group
for Gla-300 (0.71 U/kg) and Gla-100 (0.66 U/kg), and lowest doses in
the ≤0.40 nmol/L FCP group (Gla-300: 0.43 U/kg; Gla-100: 0.35 U/kg)
(Table 1, Figure S2). The mean Gla-300 dose increments were consis-
tently higher in each FCP group compared with Gla-100, with the
highest end of study ratio of doses in the ≤0.40 nmol/L group, and low-
est in the >1.20 nmol/L FCP group (Table 1).
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3.4 | Hypoglycaemia
The incidence and event rate of anytime (PG ≤ 3.9 mmol/L or severe)
and nocturnal (PG ≤ 3.9 mmol/L or severe) hypoglycaemia decreased
with each higher FCP step in both insulin groups, being lowest in the
>1.20 nmol/L FCP group (Tables 1 and S2). However, in Gla-300 par-
ticipants, the incidence was numerically and consistently lower versus
Gla-100 across all FCP groups with relative risk reductions of 13%-
18% for anytime (PG ≤ 3.9 mmol/L or severe) hypoglycaemia and
21%-48% for nocturnal hypoglycaemia. The incidence and event rate
of severe hypoglycaemia over 26 weeks was very low with both insu-
lin treatments, such that no meaningful differences could be
expected.
Analyses using a more stringent PG cut-off(PG < 3.0 mmol/L;
<54 mg/dL) yielded similar findings as observed with PG
≤ 3.9 mmol/L (Tables 1 and S2). However, in the >0.40-1.20 nmol/L
FCP group, with higher participant numbers, the relative risk reduc-
tions were greater and more statistically certain for Gla-300 versus
Gla-100.
Binomial regression analysis revealed a strong negative rela-
tionship between both anytime and nocturnal hypoglycaemia event
rate and baseline C-peptide for both insulins, irrespective of the PG
cut-off definition used (Figure 1). Furthermore, the plots show a
consistently lower hypoglycaemia risk with Gla-300 versus Gla-100
across different FCP levels, predominantly with decreasing FCP
levels.
TABLE 1 Outcome measures at 26 weeks and change from baseline according to baseline fasting C-peptide groups
Fasting C-peptide group
≤0.40 nmol/L >0.40-1.20 nmol/L >1.20 nmol/L
Gla-300 Gla-100 Gla-300 Gla-100 Gla-300 Gla-100
HbA1c n = 52 n = 43 n = 308 n = 298 n = 69 n = 83
Baseline (%) 8.68 (1.20) 8.65 (1.22) 8.49 (1.01) 8.59 (1.05) 8.47 (1.07) 8.45 (1.09)
Week 26, % 7.12 (0.95) 7.03 (0.61) 7.08 (0.96) 7.01 (0.93) 6.99 (0.97) 7.10 (1.09)
Change from baseline, % unit −1.45 (1.09) −1.67 (1.22) −1.40 (1.07) −1.57 (1.16) −1.35 (1.24) −1.39 (1.21)
Baseline (mmol/mol) 71.4 (13.1) 71.0 (13.3) 69.3 (11.0) 70.4 (11.5) 69.1 (11.7) 68.9 (11.9)
Week 26, mmol/mol 54.3 (10.4) 53.3 (6.6) 53.9 (10.5) 53.1 (10.1) 52.9 (10.6) 54.1 (11.9)
Change from baseline, mmol/mol −15.9 (11.9) −17.7 (13.3) −15.3 (11.7) −17.2 (12.6) −14.8 (13.5) −15.2 (13.2)
FPG, mmol/L n = 42 n = 34 n = 258 n = 232 n = 53 n = 70
Baseline 10.0 (3.6) 10.1 (2.6) 9.9 (2.8) 10.1 (2.8) 10.3 (2.8) 11.0 (3.5)
Week 26 6.4 (1.9) 6.1 (1.8) 6.6 (2.2) 6.2 (1.7) 7.1 (2.2) 6.8 (2.0)
Change from baseline −3.7 (3.8) −4.2 (2.4) −3.3 (3.2) −3.8 (2.9) −3.0 (3.2) −4.0 (3.1)
Insulin dose n = 45 n = 35 n = 259 n = 233 n = 56 n = 69
Week 26, U/kg 0.43 (0.25) 0.35 (0.21) 0.63 (0.29) 0.53 (0.23) 0.71 (0.28) 0.66 (0.24)
Change from baseline, U/kg 0.23 (0.25) 0.15 (0.22) 0.44 (0.29) 0.33 (0.22) 0.52 (0.27) 0.47 (0.23)
Hypoglycaemia incidence n = 52 n = 43 n = 310 n = 303 n = 70 n = 86
Anytime (≤3.9 mmol/L or severe), % people 65.4 76.7 47.1 53.8 28.6 34.9
Relative risk 0.86 (0.66-1.10) 0.87 (0.75-1.02) 0.82 (0.51-1.31)
Anytime (<3.0 mmol/L or severe), % people 17.3 27.9 8.7 16.5 8.6 10.5
Relative risk 0.62 (0.29-1.34) 0.53 (0.34-0.82) 0.82 (0.31-2.18)
Nocturnal (≤3.9 mmol/L or severe), % people 36.5 46.5 17.4 22.8 7.1 14.0
Relative risk 0.79 (0.49-1.27) 0.76 (0.56-1.05) 0.52 (0.19-1.43)
Nocturnal (<3.0 mmol/L or severe), % people 11.5 14.0 3.2 6.9 1.4 2.3
Relative risk 0.83 (0.29-2.38) 0.46 (0.22-0.97) 0.77 (0.12-4.86)
Severe, n peoplea 0 0 3 4 1 0
Body weight, kg n = 47 n = 36 n = 267 n = 248 n = 57 n = 73
Baseline 78.5 (19.5) 75.6 (17.0) 94.7 (22.0) 95.8 (21.3) 109.8 (22.9) 105.8 (23.1)
Week 26 79.5 (20.8) 76.0 (18.1) 95.2 (21.6) 96.0 (22.0) 108.5 (24.0) 106.2 (23.2)
Change from baseline 0.7 (3.4) 1.1 (3.6) 0.7 (3.8) 0.8 (4.0) −1.1 (3.8) 0.1 (3.2)
Note: Values are means (SD) or as stated. Group numbers vary with missing values.
athird party assistance required; Gla-300, glargine 300 U/mL; Gla-100, glargine 100 U/mL; relative risk (95% CI) for Gla-300 compared with Gla-100.
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3.5 | Body weight
Baseline and 26-week mean body weights were least in people with
the lowest FCP values compared with higher FCP (Table 1). Mean gain
in body weight was greatest in ≤0.40 nmol/L FCP groups at 26 weeks,
0.7 kg with Gla-300 and 1.2 kg with Gla-100, and least in the
>1.20 nmol/L FCP groups (0.1 kg with Gla-100), whereas reduction
was found with Gla-300 (−1.1 kg).
4 | DISCUSSION
This post hoc analysis of the EDITION 3 trial using participant-level
data of 867 insulin-naïve T2D people identified individuals at different
risk of hypoglycaemia over 6 months of basal insulin treatment when
stratified by baseline FCP, confirming recent findings from a larger
pooled analysis of nine studies with Gla-100.6 Moreover, at similar
glycaemic control with both insulins across different baseline FCP
levels, Gla-300 treatment appeared to be associated with a lower risk
of hypoglycaemia compared with Gla-100. However, a significant rel-
ative risk reduction was only found for anytime and nocturnal clini-
cally important hypoglycaemia with PG < 3.0 mmol/L (level 2;
ADA/EASD10) in people with FCP levels 0.40-1.20 nmol/L, rep-
resenting the largest group of study participants. For the other smaller
FCP groups (<0.40 and >1.20 nmol/L) we found a similarly consistent
and clear trend of relative risk reduction with Gla-300 lacking signifi-
cance, presumably because of the limited number of people in each
FCP group. With regression analysis (Figure 1), the advantage of Gla-
300 over Gla-100 appeared even more marked for absolute rate
reduction, suggesting that people with T2D and lower FCP who have
higher event rates might benefit more than those with higher FCP and
lower event rates, most probably representing people with insulin
resistance.
As observed in other glargine T2D studies,6 the current post hoc
analysis of the EDITION 3 trial re-emphasizes that the differences in
baseline FCP levels and associated phenotypes between groups
largely account for the heterogeneity of outcome responses observed
at 26 weeks after beginning basal insulin therapy and supports the
recently proposed cluster classification of diabetes.1,3 About 11% of
people in the EDITION 3 trial had a low baseline FCP (≤0.40 nmol/L).
As expected, this minority group had a tendency for longer duration
of known diabetes (9-11 years) and a slightly higher baseline HbA1c
(+0.2% units; +2 mmol/mol) compared with those with higher FCP
levels (Tables 1 and S1). Notably, those participants had the lowest
body weight/BMI, both at baseline and 26 weeks, and experienced
the highest incidence and number of hypoglycaemia events. By con-
trast, participants in the highest FCP group are obese, probably more
insulin-resistant, with lower eGFR levels at baseline and lower risk of
F IGURE 1 Relationship of
frequency of confirmed
hypoglycaemia (events/person-year)
at anytime with PG ≤ 3.9 mmol/L or
severe (A), and PG <3.0 mmol/L or
severe (C), nocturnal with PG
≤3.9 mmol/L or severe (B), and PG
<3.0 mmol/L or severe (D), according
to baseline fasting C-peptide levels.
Plots are derived from negative
binomial regression analysis and
displayed with 95% confidence
intervals. Vertical dotted lines indicate
FCP cut-offs used for the
stratification of groups. Gla-300,
glargine 300 U/mL; Gla-100, glargine
100 U/mL; PG, plasma glucose
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hypoglycaemia. Cluster analyses have confirmed a strong association
between the presence of insulin resistance and the development of
nephropathy in T2D.1,3
The heterogeneity of study participants with T2D in the EDITION
3 trial was further shown by their different insulin dose requirements to
achieve similar glycaemic control. The final basal insulin doses for Gla-
300 and Gla-100 were least in the lowest FCP group, suggesting that this
insulin-deficient group was more insulin-sensitive1,3,11,12 and almost dou-
bled in the highest FCP group. The need for higher doses of Gla-300 ver-
sus Gla-100 to achieve similar glycaemic control has been previously
discussed.6 Using a predefined FCP cut-off(e.g. >0.40 nmol/L) and mea-
surement of other biomarkers such as anti-GAD 65 antibodies as inclu-
sion criteria could reduce the level of heterogeneous people in T2D
studies, excluding people with LADA or MODY diabetes.13,14
EDITION 3 included insulin-naïve people with T2D. Even in this
typically low-risk population for hypoglycaemia, FCP identified a non-
negligible subgroup (11%) at a higher risk of hypoglycaemia. Further,
the effects of Gla-300 on risk reduction of hypoglycaemia were
clearly not confounded by sulfonylurea/glinides, as these drugs were
excluded from use in this study.
A limitation of this post hoc analysis is that it describes observa-
tions associated with retrospectively defined baseline FCP subgroups
and by necessity has used a descriptive analysis; confounding factors
other than fasting C-peptide levels may also have contributed to the
difference in hypoglycaemia risk with Gla-300 and Gla-100.
In summary, this post hoc analysis in insulin-naïve people with T2D
commencing basal insulin as either Gla-300 or Gla-100 after inade-
quate glycaemic control on oral therapy indicates that a notable minor-
ity of people (11%) with lower FCP are at higher risk of hypoglycaemia
compared with those with higher FCP. The study also suggests that
Gla-300 is associated with a lower relative hypoglycaemia risk com-
pared with Gla-100, clearly shown for FCP levels of >0.40 to
1.20 nmol/L and by consistent trends in favour of Gla-300 in the other
FCP groups. Our findings reaffirm that in the subgroup with low FCP,
basal insulin should be carefully titrated to limit hypoglycaemia.
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